Q4217 HCPCS Reimbursement & Policy Benchmarks

HCPCS Level II code Q4217 designates a per-square-centimeter add-on for biologic or advanced wound care products marketed as Woundfix/Biowound variants. It is billed in addition to a primary wound procedure and captures area-based use of topical biologic dressings or graft-like products. Nationally, area-based wound product codes matter because they affect payment granularity, utilization tracking for advanced wound therapies, and claims consistency across care settings.

This analysis covers major national payers: Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what Q4217 represents clinically, where it is typically billed, and which payers are relevant for coverage and coding discussions. The publication summarizes available benchmarks, common billing modifiers, and policy considerations that influence coding practice for add-on wound care products. It also outlines clinical context for use — namely adjunctive biologic dressings applied per square centimeter during wound care procedures — and notes where input data are not available.

The report is organized to help coding managers, revenue integrity teams, and clinical leaders understand the code’s purpose, typical sites of service, and the payer landscape to inform accurate claim submission and policy discussions.

Billing Code Overview

HCPCS Level II code Q4217 describes a per-square-centimeter add-on product identified as "Woundfix, biowound, woundfix plus, biowound plus, woundfix xplus or biowound xplus." This code represents a biologic or advanced wound care adjunct billed in addition to a primary wound procedure and is reported per square centimeter.

Service type: Advanced wound care adjunct, biologic wound dressing or topical wound product billed as an add-on per area treated.
Typical site of service: Wound care settings such as outpatient wound clinics, hospital outpatient departments, physician offices, and other ambulatory care locations where wound debridement or advanced wound therapies are performed.

Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.

Clinical Context

A 68-year-old patient with a chronic, non-healing lower-extremity venous ulcer presents to a wound care clinic for advanced topical biologic therapy. Following wound bed preparation, debridement, and assessment for active infection, the clinician measures the ulcer surface area and applies a per-square-centimeter topical bioactive wound matrix product billed as Q4217 (Woundfix/Biowound variants) as an add‑on to the primary procedure. The clinical workflow typically includes: initial evaluation and documentation of wound size, etiology, and prior treatments; necessary wound cleansing and selective debridement (sharp or enzymatic) as indicated; application of the per‑cm2 biologic matrix to the prepared wound bed; securement with appropriate dressings; and scheduling of follow‑up visits for reassessment and potential repeat applications. Typical sites of service are outpatient wound care centers, hospital outpatient departments, physician offices (dermatology, general surgery, vascular surgery), and skilled nursing facilities. The typical patient scenario includes comorbidities such as diabetes mellitus, peripheral vascular disease, or chronic venous insufficiency that impair wound healing, requiring adjunctive biologic topical therapy billed as an add‑on per square centimeter product.

Coding Specifications

Modifier	Description	When to Use
`22`	Increased procedural services	When work or complexity substantially exceeds typical for the primary procedure performed with the add‑on product

Taxonomy Code	Specialty	Notes
207Q00000X	Wound Care (Physician)	Physicians specializing in wound management who perform assessment, debridement, and biologic applications
207L00000X	General Surgery	Surgeons who perform operative debridement and complex wound procedures where topical biologics may be applied
207VG0100X	Vascular Surgery	Vascular specialists managing ischemic or venous ulcers requiring adjunctive topical products
363A00000X	Nurse Practitioner	Advanced practice clinicians in wound care clinics who apply topical biologic products and manage follow‑up
170P00000X	Dermatology	Dermatologists who treat chronic skin ulcers and apply adjunctive wound matrix products

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`E11.621`	Type 2 diabetes mellitus with foot ulcer	Diabetic foot ulcers frequently require advanced topical biologic products to promote healing after debridement
`I83.019`	Varicose veins of right lower extremity with ulcer, unspecified site	Venous stasis ulcers commonly receive biologic wound matrices as adjunctive therapy
`I87.2`	Venous insufficiency (chronic)	Chronic venous insufficiency predisposes to nonhealing ulcers treated with per‑cm2 topical products
`L97.324`	Non-pressure chronic ulcer of left calf with fat layer exposed	Non‑healing lower‑extremity ulcers with tissue loss where topical biologic matrices are applied
`L89.309`	Pressure ulcer of sacral region, stage 3	Pressure injuries with full‑thickness tissue loss may be treated with adjunctive biologic products after wound bed preparation

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`11042`	Debridement, subcutaneous tissue; first 20 sq cm or less	Commonly performed immediate prior to application of a topical biologic matrix to prepare the wound bed
`11043`	Debridement, muscle and/or fascia; first 20 sq cm or less	Performed for deeper debridement when the wound requires more extensive tissue removal before product application
`97597`	Removal of devitalized tissue from wounds; selective debridement, without anesthesia (first 20 sq cm or less)	Outpatient selective debridement often performed in wound clinic prior to applying the add‑on biologic product
`97606`	Negative pressure wound therapy (NPWT) using disposable non‑commercial device, including dressing changes, total wound(s) surface area up to 50 sq cm	May be used before or after biologic application to manage exudate and promote graft/matrix adherence
`15271`	Split‑thickness autograft, trunk, arms, legs; first 100 sq cm or less, or each additional 100 sq cm	In complex wounds where autografting is performed, the per‑cm2 biologic product may be used adjunctively or on donor/recipient sites

OpenPayer

Summary & Overview

HCPCS Q4217: Woundfix/Biowound Add-On, Per Square Centimeter